PE20210549A1 - Derivado de amino-metil piperidina como inhibidor de quinasa - Google Patents
Derivado de amino-metil piperidina como inhibidor de quinasaInfo
- Publication number
- PE20210549A1 PE20210549A1 PE2020000794A PE2020000794A PE20210549A1 PE 20210549 A1 PE20210549 A1 PE 20210549A1 PE 2020000794 A PE2020000794 A PE 2020000794A PE 2020000794 A PE2020000794 A PE 2020000794A PE 20210549 A1 PE20210549 A1 PE 20210549A1
- Authority
- PE
- Peru
- Prior art keywords
- amino
- kinase inhibitor
- methyl piperidine
- piperidine derivative
- present
- Prior art date
Links
- KJWNKJWHMQSPNZ-UHFFFAOYSA-N 1-methylpiperidin-2-amine Chemical class CN1CCCCC1N KJWNKJWHMQSPNZ-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente invencion se refiere a un compuesto representado por la siguiente Formula 1, donde X1 es N-R1, O, S; X2 es CH, N; R1 es C1-5 alquil, C3-6 cicloalquil, C1-5 alquil sustituido con terbutoxicarbonilamino; R2 es H, C1-5 aklquilo, halofeno; R3 es H, C1-5alquil. El compuesto segun la presente invencion puede usarse de manera util para la prevencion o el tratamiento de enfermedades que estan asociadas con acciones inhibidoras de quinasas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170183062A KR102577242B1 (ko) | 2017-12-28 | 2017-12-28 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
| PCT/KR2018/016813 WO2019132561A1 (ko) | 2017-12-28 | 2018-12-28 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210549A1 true PE20210549A1 (es) | 2021-03-17 |
Family
ID=67067897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000794A PE20210549A1 (es) | 2017-12-28 | 2018-12-28 | Derivado de amino-metil piperidina como inhibidor de quinasa |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11407754B2 (es) |
| EP (1) | EP3733674B1 (es) |
| JP (1) | JP7024091B2 (es) |
| KR (1) | KR102577242B1 (es) |
| CN (1) | CN111527088B (es) |
| AU (1) | AU2018394996B2 (es) |
| BR (1) | BR112020013237A2 (es) |
| CA (1) | CA3085160C (es) |
| CL (1) | CL2020001749A1 (es) |
| CO (1) | CO2020007156A2 (es) |
| DO (1) | DOP2020000111A (es) |
| EC (1) | ECSP20035588A (es) |
| ES (1) | ES2924225T3 (es) |
| MA (1) | MA51433A (es) |
| MX (1) | MX2020006798A (es) |
| MY (1) | MY196572A (es) |
| PE (1) | PE20210549A1 (es) |
| RU (1) | RU2756505C1 (es) |
| SA (1) | SA520412334B1 (es) |
| SG (1) | SG11202004916YA (es) |
| TN (1) | TN2020000081A1 (es) |
| WO (1) | WO2019132561A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10392368B2 (en) | 2017-08-01 | 2019-08-27 | Theravance Biopharma R&D Ip, Llc | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors |
| KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
| RU2758370C1 (ru) | 2017-12-28 | 2021-10-28 | Даевунг Фармасьютикал Ко., Лтд. | Производные оксифторпиперидина в качестве ингибитора киназы |
| WO2020154350A1 (en) | 2019-01-23 | 2020-07-30 | Theravance Biopharma R&D Ip, Llc | Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors |
| KR102228668B1 (ko) * | 2019-10-08 | 2021-03-17 | (주)부흥산업사 | 메틸피퍼리딘 아미노피롤로 피리미딘의 제조방법 |
| CN112824381B (zh) * | 2019-11-21 | 2024-04-26 | 广东东阳光药业股份有限公司 | 一种哌啶胺的制备方法 |
| US11697648B2 (en) | 2019-11-26 | 2023-07-11 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as JAK inhibitors |
| CN113214265B (zh) * | 2020-01-21 | 2023-07-07 | 江苏先声药业有限公司 | 嘧啶并五元环类化合物 |
| WO2021147953A1 (zh) * | 2020-01-21 | 2021-07-29 | 江苏先声药业有限公司 | 嘧啶并五元环类衍生物及其应用 |
| CN115023428A (zh) * | 2020-01-21 | 2022-09-06 | 江苏先声药业有限公司 | 嘧啶并吡咯类化合物 |
| TW202214643A (zh) * | 2020-09-22 | 2022-04-16 | 大陸商江蘇先聲藥業有限公司 | 嘧啶并吡咯類化合物 |
| CN114315838B (zh) * | 2020-09-30 | 2024-09-03 | 江苏先声药业有限公司 | 嘧啶并吡咯类化合物 |
| WO2023165562A1 (zh) * | 2022-03-02 | 2023-09-07 | 南京明德新药研发有限公司 | 含氮杂环类化合物及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| EP3311818A3 (en) | 2008-07-16 | 2018-07-18 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| WO2010129053A2 (en) | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
| HUE032515T2 (en) | 2010-06-23 | 2017-09-28 | Hanmi Science Co Ltd | New condensed pyrimidine derivatives for inhibiting tyrosine kinase activity |
| CA2847540C (en) * | 2011-09-22 | 2016-05-17 | Pfizer Inc. | Pyrrolopyrimidine and purine derivatives |
| MX361992B (es) * | 2012-08-06 | 2018-12-19 | Acea Biosciences Inc | Compuestos de pirrolopirimidina novedosos como inhibidores de proteínas quinasas. |
| WO2014073987A1 (en) | 2012-11-08 | 2014-05-15 | Compac Technologies Limited | Article carrier for a grading apparatus |
| WO2014113429A2 (en) | 2013-01-16 | 2014-07-24 | Signal Pharmaceuticals, Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
| KR101879422B1 (ko) | 2013-09-18 | 2018-07-17 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Btk 및/또는 jak3 키나제의 활성을 억제하는 화합물 |
| KR101930603B1 (ko) | 2013-12-05 | 2018-12-18 | 화이자 인코포레이티드 | 피롤로[2,3-d]피리미디닐, 피롤로[2,3-b]피라지닐 및 피롤로[2,3-d]피리디닐 아크릴아미드 |
| CN105732637B (zh) | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| AU2016369584A1 (en) | 2015-12-16 | 2018-07-19 | Southern Research Institute | Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof |
| US10961247B2 (en) * | 2016-06-30 | 2021-03-30 | Daewoong Pharmaceutical Co., Ltd. | Pyrazolopyrimidine derivatives as kinase inhibitor |
| CN106432294B (zh) | 2016-09-19 | 2018-01-30 | 淮北师范大学 | 发光配合物及其制备方法 |
| KR102032418B1 (ko) | 2017-06-15 | 2019-10-16 | 한국화학연구원 | 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| RU2758370C1 (ru) | 2017-12-28 | 2021-10-28 | Даевунг Фармасьютикал Ко., Лтд. | Производные оксифторпиперидина в качестве ингибитора киназы |
| KR102577241B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체 |
| KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
-
2017
- 2017-12-28 KR KR1020170183062A patent/KR102577242B1/ko active IP Right Grant
-
2018
- 2018-12-28 EP EP18897615.3A patent/EP3733674B1/en active Active
- 2018-12-28 MY MYPI2020002466A patent/MY196572A/en unknown
- 2018-12-28 PE PE2020000794A patent/PE20210549A1/es unknown
- 2018-12-28 CN CN201880083535.6A patent/CN111527088B/zh active Active
- 2018-12-28 WO PCT/KR2018/016813 patent/WO2019132561A1/ko unknown
- 2018-12-28 RU RU2020124575A patent/RU2756505C1/ru active
- 2018-12-28 JP JP2020534937A patent/JP7024091B2/ja active Active
- 2018-12-28 MX MX2020006798A patent/MX2020006798A/es unknown
- 2018-12-28 SG SG11202004916YA patent/SG11202004916YA/en unknown
- 2018-12-28 ES ES18897615T patent/ES2924225T3/es active Active
- 2018-12-28 CA CA3085160A patent/CA3085160C/en active Active
- 2018-12-28 MA MA051433A patent/MA51433A/fr unknown
- 2018-12-28 US US16/770,213 patent/US11407754B2/en active Active
- 2018-12-28 AU AU2018394996A patent/AU2018394996B2/en active Active
- 2018-12-28 TN TNP/2020/000081A patent/TN2020000081A1/en unknown
- 2018-12-28 BR BR112020013237-3A patent/BR112020013237A2/pt unknown
-
2020
- 2020-06-10 DO DO2020000111A patent/DOP2020000111A/es unknown
- 2020-06-11 CO CONC2020/0007156A patent/CO2020007156A2/es unknown
- 2020-06-25 SA SA520412334A patent/SA520412334B1/ar unknown
- 2020-06-26 CL CL2020001749A patent/CL2020001749A1/es unknown
- 2020-06-29 EC ECSENADI202035588A patent/ECSP20035588A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7024091B2 (ja) | 2022-02-22 |
| ECSP20035588A (es) | 2020-07-31 |
| SA520412334B1 (ar) | 2022-11-03 |
| ES2924225T3 (es) | 2022-10-05 |
| KR20190080541A (ko) | 2019-07-08 |
| WO2019132561A8 (ko) | 2020-06-11 |
| NZ765152A (en) | 2024-02-23 |
| AU2018394996A2 (en) | 2020-07-16 |
| CO2020007156A2 (es) | 2020-06-19 |
| WO2019132561A1 (ko) | 2019-07-04 |
| KR102577242B1 (ko) | 2023-09-11 |
| AU2018394996B2 (en) | 2021-08-05 |
| EP3733674A1 (en) | 2020-11-04 |
| US20210188854A1 (en) | 2021-06-24 |
| EP3733674B1 (en) | 2022-06-29 |
| MY196572A (en) | 2023-04-19 |
| CN111527088B (zh) | 2022-12-30 |
| US11407754B2 (en) | 2022-08-09 |
| DOP2020000111A (es) | 2020-09-30 |
| SG11202004916YA (en) | 2020-06-29 |
| EP3733674A4 (en) | 2021-06-09 |
| CA3085160A1 (en) | 2019-07-04 |
| TN2020000081A1 (en) | 2022-01-06 |
| CA3085160C (en) | 2021-12-07 |
| RU2756505C1 (ru) | 2021-10-01 |
| MA51433A (fr) | 2021-04-07 |
| CL2020001749A1 (es) | 2020-11-06 |
| CN111527088A (zh) | 2020-08-11 |
| BR112020013237A2 (pt) | 2020-12-01 |
| MX2020006798A (es) | 2020-09-03 |
| AU2018394996A1 (en) | 2020-06-25 |
| JP2021507923A (ja) | 2021-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210549A1 (es) | Derivado de amino-metil piperidina como inhibidor de quinasa | |
| PE20210548A1 (es) | Derivado de amino-fluoropiperidina como inhibidor de quinasa | |
| CU20200046A7 (es) | Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47 | |
| NI201900012A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| ECSP20035590A (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
| PE20201500A1 (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades | |
| CR20110492A (es) | Compuestos tetracíclicos | |
| BR112015027432A2 (pt) | 3-(4-isobutil-2-metilfenil)propanal como ingrediente de perfume | |
| UY37774A (es) | Compuestos 5-cianoindol sustituidos y usos de los mismos | |
| NZ746906A (en) | Oxaborole esters and uses thereof | |
| CR20160562A (es) | Péptidos como agonistas de la oxitocina | |
| PE20151669A1 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| CU20200038A7 (es) | Compuestos derivados de pirazolo-pirrolo-pirimidina-diona como inhibidores de p2x3 | |
| BR112023017834A2 (pt) | Inibidores de lrrk2 cinase macrocíclicos | |
| CR20160142A (es) | Pirido [4,3-b]pirazín-2-carboxamidas como agentes neurogénicos para el tratamiento de trastornos neurodegenerativos | |
| MX2016014993A (es) | Estabilizador altamente eficaz. | |
| CO2019007836A2 (es) | Derivados de pirrolotriazina como inhibidor de cinasas | |
| BR112017013266A2 (pt) | processo para preparação de um composto, composto, e, usos de um composto e de uma dispersão. | |
| CO2018007788A2 (es) | Compuesto novedoso de ácido bisfosfónico | |
| CR20170058A (es) | Un derivado de tetrahidropirrolo[3,4-d][1,3]tiazina como inhibidor de bace | |
| BR112013028368A2 (pt) | novos compostos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona e octahidropiridinona | |
| ES2670477R1 (es) | Procedimiento para la preparacion de la 17beta-hidroxi-des-a-androst-9,10-en-5-ona | |
| BR112022010871A2 (pt) | Composições farmacêuticas oftalmológicas | |
| AR108837A1 (es) | Formas sólidas cristalinas de un inhibidor de bet | |
| NZ748746A (en) | Pyrazolopyrimidine derivatives as kinase inhibitor |